Gonadorelin: synthetic reproductive hormone signal (GnRH)
A lab-made copy of the brain's own hormone that tells the pituitary to release testosterone- and estrogen-driving hormones; once FDA-approved (Factrel, Lutrepulse, now discontinued) and used off-label today.
- Class
- Gonadotropin-releasing hormone (GnRH) — synthetic decapeptide
- Status
- Historically FDA-approved (Factrel, diagnostic; Lutrepulse, pulsatile ovulation induction). Both US commercial products currently discontinued. No currently marketed FDA-approved gonadorelin product in the US. Compounding access narrowing following 2024 FDA 503A safety review.
- Best-supported effect
- Pituitary LH/FSH stimulation in diagnostic pituitary challenge testing (Factrel approval, human) and pulsatile ovulation induction via pump in hypothalamic amenorrhea (Lutrepulse approval, human clinical trials). The widely discussed TRT-adjunct use (testicular preservation during exogenous testosterone therapy) has no RCT evidence base and faces documented pharmacokinetic limitations.
- Main caveat
- Both FDA-approved US products are commercially discontinued. The use case driving most current demand — TRT testicular preservation — has no randomized controlled trial support and faces pharmacokinetic obstacles vs. hCG. WADA prohibited status requires independent verification (source conflict present).
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Gonadorelin is a synthetic copy of the body's own gonadotropin-releasing hormone (GnRH) — the 10-amino-acid signal that sits at the very top of the reproductive hormone chain. Made in the hypothalamus and released in short pulses, GnRH is what tells the pituitary gland to produce the hormones that drive testosterone, estrogen, and fertility. The stored sequence (QHWSYGLRPG) is a one-letter shorthand; the actual molecule has a pyroglutamate cap at the N-terminus and an amide group at the C-terminus, both absent from the raw letters but part of the endogenous structure.
Gonadorelin was approved by the FDA in two distinct clinical roles. As Factrel (Wyeth/Ayerst), it was approved for a single-injection pituitary function test — a diagnostic challenge to evaluate how well the pituitary responds to GnRH. As Lutrepulse (Ferring), it was approved for pulsatile pump-delivered ovulation induction in women with primary hypothalamic amenorrhea. Both US commercial products are now discontinued, though the historical FDA approval remains on record. Canada re-approved a subcutaneous Lutrepulse formulation in 2012. There is currently no marketed FDA-approved gonadorelin product in the US.
Contemporary interest in compounded gonadorelin is driven largely by TRT clinics using it as an hCG alternative for testicular preservation in men on exogenous testosterone. This use is off-label, lacks randomized controlled trial support, and faces a pharmacokinetic mismatch: gonadorelin's plasma half-life of approximately 2–4 minutes means subcutaneous multi-day injection schedules produce brief pituitary stimulation episodes rather than anything approximating physiological pulsatile delivery.
History
The structure of gonadotropin-releasing hormone was determined independently by Andrew Schally and Roger Guillemin in the early 1970s — work recognized by the 1977 Nobel Prize in Physiology or Medicine. Schally's group identified the sequence as a 10-residue decapeptide and characterized its role as the hypothalamic trigger for pituitary LH and FSH release. GnRH regulation of pituitary gonadotropin output and HPG axis signaling has been extensively studied since, with the molecular details of pulsatile stimulation versus continuous desensitization now well-characterized (Stamatiades et al., Molecular and Cellular Endocrinology, 2018).
Gonadorelin entered human clinical use through the FDA-approved Factrel and Lutrepulse products. The veterinary pharmaceutical industry adopted GnRH analogs for livestock reproductive synchronization, and a large body of randomized controlled trial data exists in cattle, equine, and camelid reproductive medicine. Both the Factrel and Lutrepulse US products have since been discontinued; the off-label TRT-adjunct use that now drives most demand emerged primarily in the 2010s as hCG supply tightened.
What it does
Gonadorelin is the master switch for the reproductive hormone axis. When delivered in pulses — mimicking the body's own rhythm — it prompts the pituitary gland to release LH and FSH, which then signal the testes or ovaries to produce testosterone, estrogen, and supporting hormones for fertility. Stopping that signal, rather than continuing it, is also a pharmacological tool: continuous GnRH receptor exposure has the opposite effect, shutting down the axis — the same mechanism that GnRH-agonist drugs like leuprolide exploit for prostate cancer and endometriosis treatment.
For diagnostic purposes, a single injection tests whether the pituitary is capable of responding to GnRH at all. For ovulation induction in hypothalamic amenorrhea — a condition where the hypothalamus fails to generate GnRH pulses — a programmable pump delivering pulses every 90 minutes restores the missing signal and can enable pregnancy. The TRT-adjunct use case is conceptually different: men on exogenous testosterone, whose pituitary has been suppressed by the feedback of external androgens, use gonadorelin injections to try to maintain some baseline LH output and preserve testicular volume and spermatogenesis. Whether the pharmacokinetics of subcutaneous injection adequately achieve this is the central unresolved question.
Evidence
- Human: Strong for the two approved indications — pituitary function diagnostic testing (Factrel label) and pulsatile ovulation induction in primary hypothalamic amenorrhea (Lutrepulse label, supported by clinical trial series). A published Lutrepulse efficacy and safety trial in hypothalamic amenorrhea is among the evidence cited in the literature (PMID 2122733). Pediatric GnRH challenge studies and comparative gonadorelin bioequivalency trials are published. No randomized controlled trials evaluating gonadorelin for testicular preservation or fertility in men on exogenous testosterone are identified in the available literature — the primary current use case has no RCT support.
- Animal: Extensive. A large body of randomized controlled trials in cattle, equines, llamas, and other livestock evaluate gonadorelin for ovarian synchronization, ovulation induction, and reproductive management. This veterinary literature constitutes the majority of the published RCT volume; results are not directly applicable to human therapeutic indications.
- In vitro: None identified in available sources.
Known effects
- Pituitary LH/FSH stimulation (pulsatile exposure) — FDA-approved (Factrel diagnostic label); well-established mechanistically
- Ovulation induction in primary hypothalamic amenorrhea — FDA-approved (Lutrepulse); pulsatile pump delivery
- Testicular preservation during TRT / hCG-axis maintenance — Emerging / anecdotal; mechanism plausible; no RCT evidence; pharmacokinetic mismatch documented
- Reproductive synchronization (veterinary) — Phase III / extensive RCT literature in cattle and livestock
- Continuous-exposure axis suppression — Established mechanistic consequence; the pharmacologic basis for GnRH-agonist therapeutics (not an intended therapeutic use of gonadorelin itself)
Safety signals
Safety information below is drawn from label and clinical literature; it does not constitute prescribing guidance.
- Injection site reactions — Reported in diagnostic and therapeutic use
- Headache, nausea, flushing — Reported in clinical use
- Anaphylactoid reactions — Documented including from repeated diagnostic use; known hypersensitivity is listed as a contraindication in source literature
- Pituitary desensitization and axis suppression — Occurs with continuous (non-pulsatile) exposure; the pharmacologic mechanism underlying GnRH-agonist drugs; relevant to any schedule approaching continuous stimulation
- Long-term safety of chronic subcutaneous use — Not established; approved pump therapy was time-limited (weeks to months); multi-year continuous TRT-adjunct exposure at subcutaneous doses has no formal safety dataset in available literature
Label-identified contraindication contexts include hormone-sensitive malignancy, pituitary adenoma, prior pituitary apoplexy, known hypersensitivity, and pregnancy. These are from source literature and should be verified against current label or prescribing authority.
Regulatory status
- US (FDA): Historically approved as Factrel (Wyeth/Ayerst) for pituitary function diagnostic testing and as Lutrepulse (Ferring) for pulsatile ovulation induction in hypothalamic amenorrhea. Both US commercial products have been withdrawn from the market. No currently marketed FDA-approved gonadorelin product exists in the US. In 2024 the FDA flagged gonadorelin for safety review in the 503A compounding context; access via state-licensed compounding pharmacies is narrowing.
- Canada: A subcutaneous Lutrepulse formulation was re-approved in 2012; current availability should be verified against current Health Canada listings.
- International: Human-use products vary by jurisdiction. EMA and MHRA human-use availability is described in available literature as limited. Veterinary use in livestock reproductive management is extensive internationally.
- WADA: Source conflict. One source (peptidelist) states gonadorelin is prohibited at all times under WADA category S2 (peptide hormones and their releasing factors — gonadotropin-releasing hormone and analogs). A second source states it is not on the WADA Prohibited List. These statements directly contradict each other. The current official WADA Prohibited List should be checked independently before relying on either statement.
- Controlled substance status: Not a controlled substance per available source.
Mechanism
Gonadorelin is identical in sequence to endogenous human GnRH and acts as an agonist at the GnRH receptor (GnRHR) expressed on anterior pituitary gonadotrophs. Receptor activation couples through Gq protein to phospholipase C (PLC), generating inositol trisphosphate (IP3) and diacylglycerol (DAG), which mobilize intracellular calcium and activate downstream kinase cascades leading to LH and FSH synthesis and secretion. The pulsatile regulation of GnRH signaling and its downstream effects on gonadotropin gene expression have been characterized by Stamatiades and colleagues (Molecular and Cellular Endocrinology, 2018), and the tissue-specific regulation of the GnRH receptor promoter has been studied extensively in mammals (Schang et al., Frontiers in Endocrinology, 2012).
The critical functional feature is that the pattern of receptor stimulation, not just the presence of ligand, determines the outcome. Pulsatile exposure — matching the endogenous hypothalamic rhythm of approximately every 60–120 minutes — maintains receptor sensitivity and sustains LH and FSH secretion. Pulse frequency additionally modulates the LH-to-FSH output ratio. Continuous receptor exposure produces the opposite result: receptor internalization and desensitization, with paradoxical gonadotropin suppression. This mechanism is deliberately exploited by long-acting GnRH agonists (leuprolide, triptorelin, buserelin) to suppress the HPG axis in prostate cancer and endometriosis. Gonadorelin used without adequate pulsatility risks the same suppressive outcome.
The HPG axis downstream of gonadorelin is well-established: LH acts on Leydig cells to stimulate testosterone synthesis; FSH acts on Sertoli cells to support spermatogenesis. In women, LH and FSH coordinate folliculogenesis, ovulation, and steroidogenesis. The pharmacokinetic limit of gonadorelin as an off-label TRT adjunct follows directly from its plasma half-life of approximately 2–4 minutes: subcutaneous injection at multi-day intervals produces transient pituitary LH surges rather than physiological pulsatile mimicry. This distinguishes it from hCG, which directly activates LH receptors on Leydig cells with a half-life of approximately 30 hours, offering sustained testicular stimulation from infrequent injections.
Open questions
- RCT for TRT-adjunct use: Randomized controlled trials evaluating gonadorelin versus hCG versus placebo in men on exogenous testosterone for testicular preservation and fertility are absent from available literature. This is the primary evidence gap given the compound's current demand.
- Comparative effectiveness vs. hCG: No head-to-head controlled trial comparing the two compounds for testicular preservation, spermatogenesis maintenance, or symptomatic outcomes in TRT patients has been identified. Available literature suggests hCG may perform better for most users based on pharmacokinetic reasoning and community reports, but controlled data are absent.
- Long-term safety of chronic subcutaneous use: Approved pump therapy was time-limited. Multi-year TRT-adjunct exposure at subcutaneous doses has no formal safety dataset.
- WADA status: A source conflict exists between available documents on whether gonadorelin is prohibited under WADA S2. The current official WADA Prohibited List should be checked directly.
- Regulatory trajectory: The 2024 FDA 503A compounding review may substantially alter US access. Status was pending in available literature.
- Women's health beyond hypothalamic amenorrhea: Contemporary use of pulsatile gonadorelin in broader infertility contexts is limited in available literature; US Lutrepulse discontinuation has reduced research activity.
Related peptides
- Leuprolide — a long-acting GnRH agonist that exploits continuous GnRH receptor desensitization to suppress the HPG axis; opposite functional outcome to pulsatile gonadorelin despite acting at the same receptor
- Kisspeptin — an upstream hypothalamic neuropeptide that stimulates endogenous GnRH release; activates the same HPG axis one step higher
- hCG (human chorionic gonadotropin) — acts downstream at the LH receptor on Leydig cells; the main comparator for TRT testicular preservation; longer half-life and direct gonadal action distinguish it from gonadorelin's pituitary-level mechanism
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does the unmodified version of gonadorelin (as often compounded) bind its receptor significantly worse than the cap-modified natural form?
If true, it would explain why some compounded gonadorelin products show inconsistent results in fertility clinics and TRT practices, and would push manufacturers to verify terminal chemistry before clinical use.
If gonadorelin disappears in under 5 minutes, can a shot every few days keep the testes stimulated, or does each shot only cause one brief pulse?
Each injection does still trigger one short LH surge, so the drug is not inert, but spacing doses days apart cannot mimic the every-90-minute rhythm the approved pump therapy needed. If the lasting benefit really comes from the body's own GnRH, thousands of men may be paying for a regimen that does little, which would push them toward better-proven options.
Could a single position-6 D-leucine swap (as used in leuprolide) extend gonadorelin's half-life to under an hour while staying below the level that shuts the axis down?
If such a mid-duration version exists, it could replace cumbersome pulsatile pumps with a simple injection. The catch is that anything that lengthens half-life also raises the risk of the continuous-exposure shutdown that long-acting analogs cause, so decoupling the two is the real test.
Does slow pulsing of gonadorelin lean the cell toward FSH production through the ERK/MEK1 pathway, while fast pulsing leans it toward LH?
If the pathways really split this cleanly, doctors could nudge FSH vs LH output by adjusting the pump interval. The established picture is messier: ERK, PKC and other kinases all contribute to both hormones, so a clean one-pathway-per-hormone switch is not yet proven.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.9679849743843079 | boltz-2 |
| ranking score | 0.8187000155448914 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | colabfold_local |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-22 |
▸citationbibtex
@peptide{pep10806,
sequence = {QHWSYGLRPG},
target = {gnrhr},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}